-
Recent advances in microfluidic technology of arterial thrombosis investigations Platelets (IF 3.3) Pub Date : 2024-02-23 Jingying Lin, Si Chen, Chunying Zhang, Juan Liao, Yuemei Chen, Shanying Deng, Zhigang Mao, Tonghao Zhang, Na Tian, Yali Song, Tingting Zeng
Microfluidic technology has emerged as a powerful tool in studying arterial thrombosis, allowing researchers to construct artificial blood vessels and replicate the hemodynamics of blood flow. This...
-
Platelet rich fibrin as a bioactive matrix with proosteogenic and proangiogenic properties on human healthy primary cells in vitro Platelets (IF 3.3) Pub Date : 2024-02-23 Eva Dohle, Lena Schmeinck, Kamelia Parkhoo, Robert Sader, Shahram Ghanaati
Blood concentrates like platelet rich fibrin (PRF) have been established as a potential autologous source of cells and growth factors with regenerative properties in the field of dentistry and rege...
-
Development of a super-hydrophilic anaerobic tube for the optimization of platelet-rich fibrin Platelets (IF 3.3) Pub Date : 2024-02-22 Yan Wei, Yihong Cheng, Hongjiang Wei, Yulan Wang, Xiaoxin Zhang, Richard J. Miron, Yufeng Zhang, Shanglan Qing
Horizontal platelet-rich fibrin (H-PRF) contains a variety of bioactive growth factors and cytokines that play a key role in the process of tissue healing and regeneration. The blood collection tub...
-
Increased circulating platelet-derived extracellular vesicles in severe COVID-19 disease Platelets (IF 3.3) Pub Date : 2024-02-21 Tuukka Helin, Mari Palviainen, Marja Lemponen, Katariina Maaninka, Pia Siljander, Lotta Joutsi-Korhonen
Coagulation disturbances are major contributors to COVID-19 pathogenicity, but limited data exist on the involvement of extracellular vesicles (EVs) and residual cells (RCs). Fifty hospitalized COV...
-
Glycan-Lectin interactions between platelets and tumor cells drive hematogenous metastasis Platelets (IF 3.3) Pub Date : 2024-02-19 Longqiang Shu, Shanyi Lin, Shumin Zhou, Ting Yuan
Glycosylation is a ubiquitous cellular or microenvironment-specific post-translational modification that occurs on the surface of normal cells and tumor cells. Tumor cell-associated glycosylation i...
-
Role of the NO-GC/cGMP signaling pathway in platelet biomechanics Platelets (IF 3.3) Pub Date : 2024-02-14 Aylin Balmes, Johanna G. Rodríguez, Jan Seifert, Daniel Pinto-Quintero, Akif A. Khawaja, Marta Boffito, Maike Frye, Andreas Friebe, Michael Emerson, Francesca Seta, Robert Feil, Susanne Feil, Tilman E. Schäffer
Cyclic guanosine monophosphate (cGMP) is a second messenger produced by the NO-sensitive guanylyl cyclase (NO-GC). The NO-GC/cGMP pathway in platelets has been extensively studied. However, its rol...
-
Edi(torial) 2024: action plan for change and new initiatives Platelets (IF 3.3) Pub Date : 2024-02-14 Kirk A. Taylor
Published in Platelets (Vol. 35, No. 1, 2024)
-
Antiplatelet effects of the CEACAM1-derived peptide QDTT Platelets (IF 3.3) Pub Date : 2024-02-12 Yujia Ye, Min Leng, Shengjie Chai, Lihong Yang, Longcheng Ren, Wen Wan, Huawei Wang, Longjun Li, Chaozhong Li, Zhaohui Meng
Carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1) restricts platelet activation via platelet collagen receptor GPVI/FcRγ-chain. In this study, screening against collagen-induced p...
-
Immunological platelet transfusion refractoriness: current insights from mechanisms to therapeutics Platelets (IF 3.3) Pub Date : 2024-02-05 Xiaoyu Chen, Yuhong Zhao, Yan Lv, Jue Xie
Although there have been tremendous improvements in the production and storage of platelets, platelet transfusion refractoriness (PTR) remains a serious clinical issue that may lead to various seve...
-
Transcription factor 3 is dysregulated in megakaryocytes in myelofibrosis Platelets (IF 3.3) Pub Date : 2024-02-01 Ryan J Collinson, Lynne Wilson, Darren Boey, Zi Yun Ng, Bob Mirzai, Hun S Chuah, Rebecca Howman, Carolyn S Grove, Jacques A J Malherbe, Michael F Leahy, Matthew D Linden, Kathryn A Fuller, Wendy N Erber, Belinda B Guo
Transcription factor 3 (TCF3) is a DNA transcription factor that modulates megakaryocyte development. Although abnormal TCF3 expression has been identified in a range of hematological malignancies,...
-
The efficacy of platelet rich plasma on women with poor ovarian response: a systematic review and meta-analysis Platelets (IF 3.3) Pub Date : 2024-01-12 Lingling Wu, Fenfang Su, Peixin Luo, Qingqing Dong, Mengni Ma, Guangyong Ye
Platelet-rich plasma (PRP) is a therapeutic approach that is gaining attention for its potential in the treatment of poor ovarian response. This meta-analysis aimed to systematically review and ana...
-
Gravity sedimentation reveals functionally and morphologically different platelets in human blood Platelets (IF 3.3) Pub Date : 2024-01-08 Erzsébet Ezer, Diana Schrick, Margit Tőkés-Füzesi, István Papp, Barbara Réger, Abigél Molnár, Hajnalka Ábrahám, Akos Koller, Jolán Hársfalvi, Miklós Kellermayer, Tihamér Molnár
In contrast to red blood cells, platelets float rather than sediment when a column of blood is placed in the gravitational field. By the analogy of erythrocyte sedimentation (ESR), it can be expres...
-
Utility of VerifyNow to assess the immediate pharmacodynamic response of chewed and swallowed aspirin: comparison with aggregometry Platelets (IF 3.3) Pub Date : 2024-01-03 Kevin P. Bliden, Parshotam Kundan, Danielle Kraft, Rueshil Parekh, Sahib Singh, Aravind D. Babu, Anika P. Shah, Udaya S. Tantry, Paul A. Gurbel
VerifyNow (VN) test is a less laborious method to assess pharmacodynamics (PD) compared to light transmittance aggregometry (LTA). VN assay has not been used to study the immediate PD effects of ac...
-
Identification of apolipoprotein A-I as a target of platelet tyrosine kinases Platelets (IF 3.3) Pub Date : 2023-12-15 Christine Föhrkolb, Katrin Vogel, Günter Lochnit, Peter Presek
Published in Platelets (Vol. 35, No. 1, 2024)
-
The rapid change of shear rate gradient is beneficial to platelet activation Platelets (IF 3.3) Pub Date : 2023-12-15 Tiancong Zhang, Ling Liu, Xiaojing Huang, Xuemei Gao, Xuanrong Huan, Cui He, Yuan Li
Fluid shear plays a key role in hemostasis and thrombosis, and the purpose of this study was to investigate the effect of shear gradient change rate (SGCR) on platelet reactivity and von Willebrand...
-
A case-control study of bleeding risk in children with 22q11.2 deletion syndrome undergoing cardiac surgery Platelets (IF 3.3) Pub Date : 2023-12-15 T. Blaine Crowley, Ian Campbell, Abinaya Arulselvan, David Friedman, Elaine H. Zackai, Tracy R. Geoffrion, Char Witmer, J. William Gaynor, Donna M. McDonald-McGinn, Michele P. Lambert
Previous research suggests that individuals with 22q11.2 deletion syndrome (DS) have an increased risk of bleeding following cardiac surgery. However, current guidelines for management of patients ...
-
Role of platelet count in a murine stasis model of deep vein thrombosis Platelets (IF 3.3) Pub Date : 2023-12-15 Rick Mathews, Naly Setthavongsack, Anh Le-Cook, Andy Kaempf, Jennifer M Loftis, Randall L Woltjer, Christina U Lorentz, Alexey Revenko, Monica T Hinds, Khanh P Nguyen
Platelets are core components of thrombi but their effect on thrombus burden during deep vein thrombosis (DVT) has not been fully characterized. We examined the role of thrombopoietin-altered plate...
-
Tailoring antiplatelet therapy in older patients with coronary artery disease Platelets (IF 3.3) Pub Date : 2023-12-05 Mila Kovacevic, Graziella Pompei, Vijay Kunadian
The older population represents a unique subset of patients due to a higher rate of comorbidities and risk factors, which can lead to a higher rate of ischemic and bleeding events. As a result, old...
-
Performance evaluation of PLT-H (hybrid-channel platelet) under various interferences and application studies for platelet transfusion decisions Platelets (IF 3.3) Pub Date : 2023-11-30 Qi Cai, Han Lin, Ping Guo
The hybrid-channel platelet counting method (PLT-H) is a new platelet counting technique proposed by Mindray of China. In this study, we aimed to evaluate the accuracy of this technique in various ...
-
Tissue inhibitors of metalloproteinases (TIMPs) modulate platelet ADAM10 activity Platelets (IF 3.3) Pub Date : 2023-11-30 Christine Shu Mei Lee, Amandeep Kaur, Samantha J. Montague, Sarah M. Hicks, Robert K. Andrews, Elizabeth E. Gardiner
Platelet-specific collagen receptor glycoprotein (GP)VI is stable on the surface of circulating platelets but undergoes ectodomain cleavage on activated platelets. Activation-dependent GPVI metallo...
-
C-type lectin-like receptor-2 (CLEC-2) is a key regulator of kappa-carrageenan-induced tail thrombosis model in mice Platelets (IF 3.3) Pub Date : 2023-11-27 Ryohei Yokomori, Toshiaki Shirai, Nagaharu Tsukiji, Saori Oishi, Tomoyuki Sasaki, Katsuhiro Takano, Katsue Suzuki-Inoue
Kappa-carrageenan (KCG), which is used to induce thrombosis in laboratory animals for antithrombotic drug screening, can trigger platelet aggregation. However, the cell-surface receptor and related...
-
Cryopreservation affects platelet macromolecular composition over time after thawing and differently impacts on cancer cells behavior in vitro Platelets (IF 3.3) Pub Date : 2023-11-27 Gaia Gavioli, Agnese Razzoli, Diana E. Bedolla, Erminia Di Bartolomeo, Eleonora Quartieri, Barbara Iotti, Pamela Berni, Giovanni Birarda, Lisa Vaccari, Davide Schiroli, Chiara Marraccini, Roberto Baricchi, Lucia Merolle
Cryopreservation affects platelets’ function, questioning their use for cancer patients. We aimed to investigate the biochemical events that occur over time after thawing to optimize transfusion ti...
-
Optimizing the therapeutic window of sirolimus by monitoring blood concentration for the treatment of immune thrombocytopenia Platelets (IF 3.3) Pub Date : 2023-11-20 Yun Zhang, Yao Quan, Dan Wang, Kaniel Cassady, Wenhang Zou, Jingkang Xiong, Han Yao, Xiaojuan Deng, Ping Wang, Shijie Yang, Xi Zhang, Yimei Feng
Previous studies have demonstrated that sirolimus (SRL) is an effective agent for the treatment of refractory/relapsed (R/R) ITP. However, the therapeutic window of sirolimus in the treatment of IT...
-
Genetic background of thrombocytosis in mice mimicking hereditary thrombocytosis in humans Platelets (IF 3.3) Pub Date : 2023-11-09 Hiroyuki Kimura, Masahiro Onozawa, Takanori Teshima
Published in Platelets (Vol. 34, No. 1, 2023)
-
Deep learning, 3D ultrastructural analysis reveals quantitative differences in platelet and organelle packing in COVID-19/SARSCoV2 patient-derived platelets Platelets (IF 3.3) Pub Date : 2023-11-07 Sagar S. Matharu, Cassidy S. Nordmann, Kurtis R. Ottman, Rahul Akkem, Douglas Palumbo, Denzel R. D. Cruz, Kenneth Campbell, Gail Sievert, Jamie Sturgill, James Z. Porterfield, Smita Joshi, Hammodah R. Alfar, Chi Peng, Irina D. Pokrovskaya, Jeffrey A. Kamykowski, Jeremy P. Wood, Beth Garvy, Maria A. Aronova, Sidney W. Whiteheart, Richard D. Leapman, Brian Storrie
Platelets contribute to COVID-19 clinical manifestations, of which microclotting in the pulmonary vasculature has been a prominent symptom. To investigate the potential diagnostic contributions of ...
-
Efficacy and safety of high dose recombinant human thrombopoietin in the treatment of immune thrombocytopenia Platelets (IF 3.3) Pub Date : 2023-11-08 Xiuli Wang, Hui Bi, Lin Liu, Yuebo Liu, Liefen Yin, Jin Yao, Jingxing Yu, Wei Tao, Yueping Wei, Yu Li, Lingmei Yin, Hongli Mu, Yadong Du, Zeping Zhou
The conventional dose of recombinant human thrombopoietin (rhTPO) in the treatment of immune thrombocytopenia (ITP) is 300 U/kg per day, but the clinical reaction rate is not satisfactory. Accordin...
-
α-Synuclein is the major platelet isoform but is dispensable for activation, secretion, and thrombosis Platelets (IF 3.3) Pub Date : 2023-11-05 Alexis N. Smith, Smita Joshi, Harry Chanzu, Hammodah R. Alfar, Kanakanagavalli Shravani Prakhya, Sidney W. Whiteheart
Platelets play many roles in the vasculature ensuring proper hemostasis and maintaining integrity. These roles are facilitated, in part, by cargo molecules released from platelet granules via Solub...
-
Humanized mouse models for inherited thrombocytopenia studies Platelets (IF 3.3) Pub Date : 2023-10-17 Xiaojie Wang, Maoshan Chen, Lanyue Hu, Chengning Tan, Xiaoliang Li, Peipei Xue, Yangzhou Jiang, Peipei Bao, Teng Yu, Fengjie Li, Yanni Xiao, Qian Ran, Zhongjun Li, Li Chen
Inherited thrombocytopenia (IT) is a group of hereditary disorders characterized by a reduced platelet count as the main clinical manifestation, and often with abnormal platelet function, which can...
-
Analysis of clinical characteristics and treatment efficacy in two pediatric cases of ANKRD26-related thrombocytopenia Platelets (IF 3.3) Pub Date : 2023-10-18 Congfei Pang, Xiaomei Wu, Lauriane Nikuze, Hongying Wei
ANKRD26-related thrombocytopenia (ANKRD26-RT or THC2, MIM 188 000), an autosomal dominant thrombocytopenia, is unresponsive to immunosuppressive therapy and susceptible to hematological malignancie...
-
Multiple myeloma and its treatment contribute to increased platelet reactivity Platelets (IF 3.3) Pub Date : 2023-10-11 Joanne L. Mitchell, Dalia Khan, Rekha H. Rana, Neline Kriek, Amanda J. Unsworth, Tanya Sage, Alexander P. Bye, Michael Laffan, Susan Shapiro, Anjan Thakurta, Henri Grech, Karthik Ramasamy, Jonathan M. Gibbins
Multiple myeloma (MM) and its precursor states, smoldering myeloma (SM) and monoclonal gammopathy of undetermined significance (MGUS) are associated with increased incidence of thrombosis, however ...
-
Special review series: provocative questions in platelet omics studies Platelets (IF 3.3) Pub Date : 2023-09-19 Ángel García, Joseph E. Aslan
Published in Platelets (Vol. 34, No. 1, 2023)
-
Anti-GPIb/IX autoantibodies are associated with poor response to dexamethasone combined with rituximab therapy in primary immune thrombocytopenia patients Platelets (IF 3.3) Pub Date : 2023-09-18 Bingjie Ding, Liu Liu, Mengjuan Li, Xuewen Song, Yuanyuan Zhang, Ao Xia, Jingyuan Liu, Hu Zhou
This retrospective study aimed to evaluate whether anti-glycoproteins (GPs) autoantibodies can be used as predictors of response to high-dose dexamethasone combined with rituximab (DXM-RTX) in the ...
-
A novel, quantitative clot retraction assay to evaluate platelet function Platelets (IF 3.3) Pub Date : 2023-09-12 Wayne T. Muraoka, Prajeeda M. Nair, Daniel N. Darlington, Xiaowu Wu, James A. Bynum, Andrew P. Cap
Abstract Blood platelets are crucial to prevent excessive bleeding following injury to blood vessels. Platelets are crucial for the formation of clots and for clot strength. Platelet activation involves aggregation, attachment to fibrin and clot retraction. Most assays that address platelet function measure platelet aggregation, not clot retraction. Here, we describe a 96-well-based clot retraction
-
Dual antiplatelet therapy is associated with high α-tubulin acetylation in circulating platelets from coronary artery disease patients Platelets (IF 3.3) Pub Date : 2023-09-12 Valentine Robaux, Shakeel Kautbally, Audrey Ginion, Mélanie Dechamps, Sibille Lejeune, Nassiba Menghoum, Luc Bertrand, Anne-Catherine Pouleur, Sandrine Horman, Christophe Beauloye
Abstract Platelet inhibition is the main treatment strategy to prevent atherothrombotic complications after acute coronary syndrome or percutaneous coronary intervention. Despite dual antiplatelet therapy (DAPT) combining aspirin and a P2Y12 receptor inhibitor, high on-treatment platelet reactivity (HPR) persists in some patients due to poor response to treatment and is associated with ischemic risk
-
Biochemical characterization of spleen tyrosine kinase (SYK) isoforms in platelets Platelets (IF 3.3) Pub Date : 2023-09-03 Pankaj Kumar Singh, Carol A. Dangelmaier, Hymavathi Reddy Vari, Alexander Y. Tsygankov, Satya P. Kunapuli
Abstract Alternate splicing is among the regulatory mechanisms imparting functional diversity in proteins. Studying protein isoforms generated through alternative splicing is therefore critical for understanding protein functions in many biological systems. Spleen tyrosine kinase (Syk) plays an essential role in ITAM/hemITAM signaling in many cell types, including platelets. However, the spectrum of
-
Treatment of immune thrombocytopenia with hetrombopag olamine tablets in a Kabuki syndrome patient with new KMT2D mutations Platelets (IF 3.3) Pub Date : 2023-08-24 Peng Peng, Ying Pan, Xueqing Lu, Hui Xu, Ziwei Zhou, Yuanqing He, Huiru Wang, Changcheng Zheng, Li Zhou
Abstract Kabuki syndrome (KS) is a rare multisystem-affecting genetic disorder, and usually accompanied with autoimmune disorders such as immune thrombocytopenic purpura (ITP). Here, we report a 16-year-old patient with Kabuki syndrome with ITP and observe the therapeutic effect of TPO agonist hetrombopag olamine tablets. The duration of maintenance therapy and follow up were both 17 months. Whole
-
Trends among platelet function, arterial calcium, and vascular function measures Platelets (IF 3.3) Pub Date : 2023-08-23 Jason Cunha, Melissa V. Chan, Bongani B. Nkambule, Florian Thibord, Amber Lachapelle, Robin E. Pashek, Ramachandran S. Vasan, Jian Rong, Emelia J. Benjamin, Naomi M. Hamburg, Ming-Huei Chen, Gary F. Mitchell, Andrew D. Johnson
Abstract Arterial tonometry and vascular calcification measures are useful in cardiovascular disease (CVD) risk assessment. Prior studies found associations between tonometry measures, arterial calcium, and CVD risk. Activated platelets release angiopoietin-1 and other factors, which may connect vascular structure and platelet function. We analyzed arterial tonometry, platelet function, aortic, thoracic
-
The prospects of microphysiological systems in modeling platelet pathophysiology in cancer Platelets (IF 3.3) Pub Date : 2023-08-23 Lopamudra D. Ghosh, Abhishek Jain
Abstract The contribution of platelets is well recognized in thrombosis and hemostasis. However, platelets also promote tumor progression and metastasis through their crosstalk with various cells of the tumor microenvironment (TME). For example, several cancer models continue to show that platelet functions are readily altered by cancer cells upon activation leading to the formation of platelet-tumor
-
Platelet extracellular vesicles are efficient delivery vehicles of doxorubicin, an anti-cancer drug: preparation and in vitro characterization Platelets (IF 3.3) Pub Date : 2023-08-14 Yu-Wen Wu, Deng-Yao Lee, Yeh-Lin Lu, Liling Delila, Ouada Nebie, Lassina Barro, Chun Austin Changou, Long-Sheng Lu, Hadi Goubran, Thierry Burnouf
Abstract Platelet extracellular vesicles (PEVs) are an emerging delivery vehi for anticancer drugs due to their ability to target and remain in the tumor microenvironment. However, there is still a lack of understanding regarding yields, safety, drug loading efficiencies, and efficacy of PEVs. In this study, various methods were compared to generate PEVs from clinical-grade platelets, and their properties
-
An oligogenic case of severe neonatal thrombocytopenia and a purportedly benign variant in GFI1B requiring reinterpretation Platelets (IF 3.3) Pub Date : 2023-08-14 Max Frenkel, April Hall, M. Stephen Meyn, Carol A. Diamond
Abstract Although thrombocytopenia in neonatal intensive care patients is rarely due to inherited disorders, the number of genetic variants implicated in platelet defects has grown dramatically with increasing genome-wide sequencing. Here we describe a case of severe, oligogenic neonatal thrombocytopenia and reinterpret a reportedly benign mutation that is likely pathogenic. Despite this patient’s
-
Platelet-derived extracellular vesicles play an important role in platelet transfusion therapy Platelets (IF 3.3) Pub Date : 2023-08-14 Zhi Cai, Junyan Feng, Nian Dong, Pan Zhou, Yuanshuai Huang, Hongwei Zhang
Abstract Extracellular vesicles (EVs) contain the characteristics of their cell of origin and mediate cell-to-cell communication. Platelet-derived extracellular vesicles (PEVs) not only have procoagulant activity but also contain platelet-derived inflammatory factors (CD40L and mtDNA) that mediate inflammatory responses. Studies have shown that platelets are activated during storage to produce large
-
High plasma soluble CLEC-2 level predicts oxygen therapy requirement in patients with COVID-19 Platelets (IF 3.3) Pub Date : 2023-08-14 Saori Oishi, Makyo Ueda, Hirokazu Yamazaki, Nagaharu Tsukiji, Toshiaki Shirai, Yuna Naito, Masumi Endo, Ryohei Yokomori, Tomoyuki Sasaki, Katsue Suzuki-Inoue
Abstract Predicting the clinical course and allocating limited medical resources appropriately is crucial during the COVID-19 pandemic. Platelets are involved in microthrombosis, a critical pathogenesis of COVID-19; however, the role of soluble CLEC-2 (sCLEC-2), a novel platelet activation marker, in predicting the prognosis of COVID-19 remains unexplored. We enrolled 108 patients with COVID-19, hospitalized
-
The complementary roles of VAMP-2, -3, and -7 in platelet secretion and function Platelets (IF 3.3) Pub Date : 2023-08-06 Smita Joshi, Kanakanagavalli Shravani Prakhya, Alexis N. Smith, Harry Chanzu, Ming Zhang, Sidney W. Whiteheart
Abstract Platelet secretion requires Soluble N-ethylmaleimide Sensitive Attachment Protein Receptors (SNAREs). Vesicle SNAREs/Vesicle-Associated Membrane Proteins (v-SNAREs/VAMPs) on granules and t-SNAREs in plasma membranes mediate granule release. Platelet VAMP heterogeneity has complicated the assessment of how/if each is used and affects hemostasis. To address the importance of VAMP-7 (V7), we
-
Effects of platelet-rich fibrin produced by three centrifugation protocols on bone neoformation in defects created in rat calvaria Platelets (IF 3.3) Pub Date : 2023-07-06 Débora de Souza Ferreira Sávio, Lucia Moitrel Pequeno da Silva, Gabriel Guerra David Reis, Ricardo Junior Denardi, Natacha Malu Miranda da Costa, Flávia Aparecida Chaves Furlaneto, Sérgio Luís Scombatti de Souza, Carlos Fernando de Almeida Barros Mourão, Richard J. Miron, Roberta Okamoto, Michel Reis Messora
Abstract This study evaluated the potential of Leukocyte-platelet-rich fibrin (L-PRF; fixed angle centrifugation protocol), Advanced-platelet-rich fibrin (A-PRF; low-speed fixed angle centrifugation protocol), and Horizontal-platelet-rich fibrin (H-PRF; horizontal centrifugation protocol) in bone neoformation in critical size defects (CSDs) in rat calvaria. Thirty-two rats were divided into groups:
-
Exploration of risk factors of platelet transfusion refractoriness and its impact on the prognosis of hematopoietic stem cell transplantation: a retrospective study of patients with hematological diseases Platelets (IF 3.3) Pub Date : 2023-07-06 Xiaofei Song, Jiaqian Qi, Xueqian Li, Meng Zhou, Jingyi He, Tiantian Chu, Yue Han
Abstract Platelet transfusion refractoriness (PTR) is an intractable issue in hematological patients, which increases bleeding risks and hospitalization costs to a great extent. We reviewed 108 patients with hematological diseases including acute leukemia, myelodysplastic syndrome, aplastic anemia, and others who received allogeneic hematopoietic stem cell transplantation (HSCT) from January 2019 through
-
First-in-human study to assess the safety, pharmacokinetics, and pharmacodynamics of BMS-986141, a novel, reversible, small-molecule, PAR4 agonist in non-Japanese and Japanese healthy participants Platelets (IF 3.3) Pub Date : 2023-07-02 Samira Merali, Zhaoqing Wang, Charles Frost, Stephanie Meadows-Shropshire, Dara Hawthorne, Jing Yang, Dietmar Seiffert
Abstract BMS-986141 is a novel, oral, protease-activated, receptor 4 (PAR4)-antagonist that exhibited robust antithrombotic activity and low bleeding risk in preclinical studies. The pharmacokinetic, pharmacodynamic, and tolerability profiles of BMS-986141 in healthy participants were assessed in a randomized, double-blind, placebo-controlled, single-ascending-dose (SAD; N = 60) study; a multiple-ascending-dose
-
Hirudin versus citrate as an anticoagulant for ROTEM platelet whole blood impedance aggregometry in thrombocytopenic patients Platelets (IF 3.3) Pub Date : 2023-06-27 Wasanthi Wickramasinghe, Bhawani Yasassri Alvitigala, Thisarika Perera, Panduka Karunanayake, Saroj Jayasinghe, Senaka Rajapakse, Praveen Weeratunga, Ananda Wijewickrama, Roopen Arya, Klaus Goerlinger, Lallindra Viranjan Gooneratne
Abstract Citrate is widely used as an anticoagulant for platelet function tests (PFTs). Due to an intrinsic inhibitory effect of citrate on platelet function, hirudin is used as an alternative. However, studies comparing the effect of these anticoagulants on rotational thromboelastometry (ROTEM) platelet whole blood impedance aggregometry in thrombocytopenic patients are scant. Cross-sectional study
-
Association between endometriosis, infertility and autoimmune antiplatelet glycoprotein VI antibodies in two patients Platelets (IF 3.3) Pub Date : 2023-06-22 Stéphane Loyau, Anne Bauters, Nathalie Trillot, Cédric Garcia, Pierre Cougoul, Hélène Pol, Camille Paris, Geoffroy Robin, Chrystèle Rubod, Bernard Payrastre, Martine Jandrot-Perrus, Sophie Voisin, Annabelle Dupont
Abstract The association between endometriosis and autoimmune diseases is well known, however no acquired platelet function defect has been described so far. We describe the case of two patients with endometriosis associated with an antiplatelet glycoprotein VI (anti-GPVI) antibody. The two women with deep pelvic endometriosis associated with secondary infertility presented a mild bleeding tendency
-
Combining human platelet proteomes and transcriptomes: possibilities and challenges Platelets (IF 3.3) Pub Date : 2023-06-14 Jingnan Huang, Johan W.M. Heemskerk, Frauke Swieringa
Abstract The anucleate human platelets contain a broad pattern of mRNAs and other RNA transcripts. The high quantitative similarity of mRNAs in megakaryocytes and platelets from different sources points to a common origin, and suggests a random redistribution of mRNA species upon proplatelet formation. A comparison of the classified platelet transcriptome (17.6k transcripts) with the identified platelet
-
Platelet glycogenolysis is important for energy production and function Platelets (IF 3.3) Pub Date : 2023-06-09 Kanakanagavalli Shravani Prakhya, Hemendra Vekaria, Daniёlle M. Coenen, Linda Omali, Joshua Lykins, Smita Joshi, Hammodah R. Alfar, Qing Jun Wang, Patrick Sullivan, Sidney W. Whiteheart
Abstract Although the presence of glycogen in platelets was established in the 1960s, its importance to specific functions (i.e., activation, secretion, aggregation, and clot contraction) remains unclear. Patients with glycogen storage disease often present with increased bleeding and glycogen phosphorylase (GP) inhibitors, when used as treatments for diabetes, induce bleeding in preclinical studies
-
Proteomics-wise, how similar are mouse and human platelets? Platelets (IF 3.3) Pub Date : 2023-06-07 Patricia Martínez-Botía, Patricia Villar, Graciela Carbajo-Argüelles, Zacaria Jaiteh, Andrea Acebes-Huerta, Laura Gutiérrez
Abstract The field of proteomics and its application to platelet biology, is rapidly and promisingly developing. Platelets (and megakaryocytes) are postulated as biosensors of health and disease, and their proteome poses as a tool to identify the specific health-disease hallmarks. Furthermore, the clinical management of certain pathologies where platelets are active players demands the development
-
How can platelet proteomics best be used to interrogate disease? Platelets (IF 3.3) Pub Date : 2023-06-05 Maria Zellner
Abstract Various modifications of proteins and the resulting proteoforms of a protein can associate with many diseases and are also significantly involved in the rapid regulation of hemostasis and thrombosis. For example, the release of prostacyclin from the intact endothelium and the consequent following phosphorylation of VASP in platelets is a post-translational regulation to keep them in a quiescent
-
Platelet counts in HFE p.C282Y/p.C282Y and wt/wt post-screening clinical evaluation participants Platelets (IF 3.3) Pub Date : 2023-06-01 James C. Barton, J. Clayborn Barton, Ronald T. Acton
Abstract Our aim was to document the effects of genotype HFE p.C282Y/p.C282Y and hemochromatosis-associated laboratory and clinical manifestations on platelet counts (PC). We compiled genotype (p.C282Y/p.C282Y or HFE wt/wt (absence of p.C282Y and p.H63D (rs1799945)), age, sex, body mass index, presence/absence of chronic fatigue, swelling/tenderness of second/third metacarpophalangeal joints, and hyperpigmentation
-
Immature platelets and cardiovascular events in patients with stable coronary artery disease Platelets (IF 3.3) Pub Date : 2023-05-29 Oliver Buchhave Pedersen, Sanne Bøjet Larsen, Steen Dalby Kristensen, Anne-Mette Hvas, Erik Lerkevang Grove
Abstract Many patients with coronary artery disease (CAD) have reduced the effect of aspirin, which may partly be explained by immature platelets. We aimed to investigate whether immature platelet markers can predict cardiovascular events in a large cohort of stable CAD patients. A total of 900 stable CAD patients were included and followed for a median of 3 years. We measured markers of immature platelets
-
How can we use proteomics to learn more about platelets? Platelets (IF 3.3) Pub Date : 2023-05-29 Joseph E. Aslan
Abstract Proteomics tools provide a powerful means to identify, detect, and quantify protein-related details in studies of platelet phenotype and function. Here, we consider how historical and recent advances in proteomics approaches have informed our understanding of platelet biology, and, how proteomics tools can be used going forward to advance studies of platelets. It is now apparent that the platelet
-
Prospective assessment of platelet function in patients undergoing elective resection of glioblastoma multiforme Platelets (IF 3.3) Pub Date : 2023-05-29 Santiago R. Leal-Noval, Manuel Casado, Cancela Palomares, José L. Narros, José L. García-Garmendia, Ginés Escolar, Diego X. Cuenca, Klaus Görlinger
Abstract This prospective study was aimed to test changes in hemostasis in patients with GBM, occurring at baseline (before surgery, time 0, T0) and 2 (T2), 24 (T24), and 48-hour (T48) after surgery. We enrolled consecutive patients subjected to GBM resection (GBR group; N = 60), laparoscopic colon cancer resection (comparative CCR group; N = 40), and healthy blood donors (HBD group; N = 40). We performed
-
F11R/JAM-A: why do platelets express a molecule which is also present in tight junctions? Platelets (IF 3.3) Pub Date : 2023-05-29 Piotr Kamola, Anna Babinska, Tomasz Przygodzki
Abstract F11 receptor (F11R)/Junctional Adhesion Molecule –A (JAM-A) is a transmembrane protein which belongs to the immunoglobulin superfamily of cell adhesion molecules. F11R/JAM-A is present in epithelial cells, endothelial cells, leukocytes, and blood platelets. In epithelial and endothelial cells, it takes part in the formation of tight junctions. In these structures, molecules of F11R/JAM-A located
-
Identification and validation of core genes in tumor-educated platelets for human gastrointestinal tumor diagnosis using network-based transcriptomic analysis Platelets (IF 3.3) Pub Date : 2023-05-22 Yuhong Jiang, Jun He, Xiaobo Wang, Chao Liu, Weihan Zhou, Dekun Liu, Zhushu Guo, Kuijie Liu
Abstract Gastrointestinal (GI) tumors have increasing incidence worldwide with their underlying mechanisms still not being fully understood. The use of tumor-educated platelets (TEPs) in liquid biopsy is a newly-emerged blood-based cancer diagnostic method. Herein, we aimed to investigate the genomic changes of TEPs in GI tumor development and their potential functions using network-based meta-analysis
-
N-methyl-D-aspartate receptor regulates the circadian clock in megakaryocytic cells and impacts cell proliferation through BMAL1 Platelets (IF 3.3) Pub Date : 2023-05-15 James I. Hearn, Mariam Alhilali, Minah Kim, Maggie L. Kalev-Zylinska, Raewyn C. Poulsen
Abstract Peripheral circadian clocks control cell proliferation and survival, but little is known about their role and regulation in megakaryocytic cells. N-methyl-D-aspartate receptor (NMDAR) regulates the central clock in the brain. The purpose of this study was to determine whether NMDAR regulates the megakaryocytic cell clock and whether the megakaryocytic clock regulates cell proliferation and
-
The effect of short-term cryopreservation on the properties and functionality of platelet-rich plasma Platelets (IF 3.3) Pub Date : 2023-05-10 Maider Beitia, Diego Delgado, Jon Mercader, Irene Gimeno, João Espregueira-Mendes, Beatriz Aizpurua, Mikel Sánchez
Abstract Platelet Rich Plasma (PRP) is a biological treatment which, thanks to its enhanced growth factors content, is widely used in the field of regenerative medicine for its reparative effects. Although it is usually used fresh immediately after preparation, its freezing for preservation for future usage could be key in increasing its versatility and new applications. To assess the suitability of